Advertisement

Infection

, Volume 47, Issue 6, pp 899–909 | Cite as

Comparison of three current Clostridioides difficile infection guidelines: IDSA/SHEA, ESCMID, and ACG guidelines

  • Abrar K. ThabitEmail author
  • Mawadah H. Alsolami
  • Nojoud A. Baghlaf
  • Raghad M. Alsharekh
  • Hadeel A. Almazmumi
  • Afrah S. Alselami
  • Fatmah A. Alsubhi
Review

Abstract

Purpose

Clostridioides difficile infection (CDI) is a widely recognized condition associated with comorbidity and decreased patient quality of life. Certain professional medical organizations develop clinical practice guidelines for major diseases. This is done in an effort to streamline the universal clinical practice and ensure that a more accurate diagnosis and better treatments are offered to respective patients for optimal outcomes. However, as new data evolve, constant update of these guidelines becomes essential. While these guidelines provide up-to-date recommendations, they are not published around the same time; thus, their recommendations may vary depending on evidence available prior to guidelines preparation and publication.

Methods

Recommendations and corresponding justifications from three major CDI guidelines between 2013 and 2017 were pooled and compared, and notable differences were highlighted while providing an insight and a final recommendation from a clinical standpoint.

Results

Most recommendations were consistent among all three guidelines. One notable difference was in the specification of candidates for CDI diagnosis, where it would be recommended to mainly test patients with three or more diarrheal episodes over 24 h, if they had no other clear reason for the diarrhea. Another conflicting point was regarding the treatment of non-severe CDI where vancomycin can be considered for older or sicker patients; however, metronidazole still remains a reasonable option based on recent data, some of which were not cited in the most recent guidelines of IDSA/SHEA.

Conclusion

Overall, it is prudent to follow these guidelines with critical appraisal to fulfill the goal of achieving optimum patient outcomes.

Keywords

Clostridioides difficile Guidelines IDSA ESCMID ACG Vancomycin 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Burgers JS, Grol R, Klazinga NS, Makela M, Zaat J. Towards evidence-based clinical practice: an international survey of 18 clinical guideline programs. Int J Qual Health Care. 2003;15:31–45.CrossRefGoogle Scholar
  2. 2.
    Feher C, Mensa J. A comparison of current guidelines of five international societies on Clostridium difficile infection management. Infect Dis Ther. 2016;5:207–30.  https://doi.org/10.1007/s40121-016-0122-1.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108:478–98.  https://doi.org/10.1038/ajg.2013.4(quiz 99).CrossRefPubMedGoogle Scholar
  4. 4.
    McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66:987–94.  https://doi.org/10.1093/cid/ciy149.CrossRefPubMedGoogle Scholar
  5. 5.
    Organization WH. Diarrhoea. https://www.who.int/topics/diarrhoea/en/. Accessed 16 Jan 2019.
  6. 6.
    Debast SB, Bauer MP, Kuijper EJ. European society of clinical microbiology and infectious diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2014;20:1–26.  https://doi.org/10.1111/1469-0691.12418.CrossRefPubMedGoogle Scholar
  7. 7.
    Thabit AK, Varugehese CA, Levine AR. Antibiotic use and duration in association with Clostridioides difficile infection in a tertiary academic medical center: a retrospective case–control study. Anaerobe. 2019;59:126–30.  https://doi.org/10.1016/j.anaerobe.2019.06.016.CrossRefPubMedGoogle Scholar
  8. 8.
    Thabit AK, Nicolau DP. Lack of correlation between Bristol Stool Scale and quantitative bacterial load in Clostridium difficile infection. Infect Dis Res Treat. 2015;8:1–4.  https://doi.org/10.4137/idrt.s23079.CrossRefGoogle Scholar
  9. 9.
    Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31:431–55.  https://doi.org/10.1086/651706.CrossRefPubMedGoogle Scholar
  10. 10.
    Teasley DG, Gerding DN, Olson MM, Peterson LR, Gebhard RL, Schwartz MJ, et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet. 1983;2:1043–6.CrossRefGoogle Scholar
  11. 11.
    Wenisch C, Parschalk B, Hasenhundl M, Hirschl AM, Graninger W. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis. 1996;22:813–8.CrossRefGoogle Scholar
  12. 12.
    Al-Nassir WN, Sethi AK, Li Y, Pultz MJ, Riggs MM, Donskey CJ. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother. 2008;52:2403–6.  https://doi.org/10.1128/AAC.00090-08.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45:302–7.  https://doi.org/10.1086/519265.CrossRefPubMedGoogle Scholar
  14. 14.
    Johnson S, Louie TJ, Gerding DN, Cornely OA, Chasan-Taber S, Fitts D, et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis. 2014;59:345–54.  https://doi.org/10.1093/cid/ciu313.CrossRefPubMedGoogle Scholar
  15. 15.
    Stevens VW, Nelson RE, Schwab-Daugherty EM, Khader K, Jones MM, Brown KA, et al. Comparative effectiveness of vancomycin and metronidazole for the prevention of recurrence and death in patients with Clostridium difficile infection. JAMA Internal Med. 2017;177:546–53.  https://doi.org/10.1001/jamainternmed.2016.9045.CrossRefGoogle Scholar
  16. 16.
    Crowell KT, Julian KG, Katzman M, Berg AS, Tinsley A, Williams ED, et al. Compliance with Clostridium difficile treatment guidelines: effect on patient outcomes. Epidemiol Infect. 2017;145:2185–92.  https://doi.org/10.1017/s0950268817000644.CrossRefPubMedGoogle Scholar
  17. 17.
    Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364:422–31.  https://doi.org/10.1056/NEJMoa0910812.CrossRefPubMedGoogle Scholar
  18. 18.
    Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis. 2012;12:281–9.  https://doi.org/10.1016/S1473-3099(11)70374-7.CrossRefPubMedGoogle Scholar
  19. 19.
    Housman ST, Thabit AK, Kuti JL, Quintiliani R, Nicolau DP. Assessment of Clostridium difficile burden in patients over time with first episode infection following fidaxomicin or vancomycin. Infect Control Hosp Epidemiol. 2016;37:215–8.  https://doi.org/10.1017/ice.2015.270.CrossRefPubMedGoogle Scholar
  20. 20.
    Thabit AK, Alam MJ, Khaleduzzaman M, Garey KW, Nicolau DP. A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin. Ann Clin Microbiol Antimicrob. 2016;15:22.  https://doi.org/10.1186/s12941-016-0140-6.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Gallagher JC, Reilly JP, Navalkele B, Downham G, Haynes K, Trivedi M. Clinical and economic benefits of fidaxomicin compared to vancomycin for Clostridium difficile infection. Antimicrob Agents Chemother. 2015;59:7007–10.  https://doi.org/10.1128/AAC.00939-15.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Goldenberg SD, Brown S, Edwards L, Gnanarajah D, Howard P, Jenkins D, et al. The impact of the introduction of fidaxomicin on the management of Clostridium difficile infection in seven NHS secondary care hospitals in England: a series of local service evaluations. Eur J Clin Microbiol Infect Dis. 2016;35:251–9.  https://doi.org/10.1007/s10096-015-2538-z.CrossRefPubMedGoogle Scholar
  23. 23.
    Musher DM, Aslam S, Logan N, Nallacheru S, Bhaila I, Borchert F, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis. 2005;40:1586–90.  https://doi.org/10.1086/430311.CrossRefPubMedGoogle Scholar
  24. 24.
    Apisarnthanarak A, Razavi B, Mundy LM. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis. 2002;35:690–6.  https://doi.org/10.1086/342334.CrossRefPubMedGoogle Scholar
  25. 25.
    Malamood M, Nellis E, Ehrlich AC, Friedenberg FK. Vancomycin enemas as adjunctive therapy for Clostridium difficile infection. J Clin Med Res. 2015;7:422–7.  https://doi.org/10.14740/jocmr2117w.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Siegfried J, Dubrovskaya Y, Flagiello T, Scipione MR, Phillips M, Papadopoulos J, et al. Initial therapy for mild to moderate Clostridium difficile infection: exploring the role of oral metronidazole versus vancomycin in 168 hospitalized patients. Infect Dis Clin Pract. 2016;24:210–6.CrossRefGoogle Scholar
  27. 27.
    Pepin J, Alary ME, Valiquette L, Raiche E, Ruel J, Fulop K, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis. 2005;40:1591–7.  https://doi.org/10.1086/430315.CrossRefPubMedGoogle Scholar
  28. 28.
    Al-Nassir WN, Sethi AK, Nerandzic MM, Bobulsky GS, Jump RL, Donskey CJ. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Clin Infect Dis. 2008;47:56–62.  https://doi.org/10.1086/588293.CrossRefPubMedGoogle Scholar
  29. 29.
    Dudley MN, McLaughlin JC, Carrington G, Frick J, Nightingale CH, Quintiliani R. Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea. A randomized double-blind trial. Arch Intern Med. 1986;146:1101–4.CrossRefGoogle Scholar
  30. 30.
    de Lalla F, Nicolin R, Rinaldi E, Scarpellini P, Rigoli R, Manfrin V, et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother. 1992;36:2192–6.CrossRefGoogle Scholar
  31. 31.
    Fekety R, Silva J, Kauffman C, Buggy B, Deery HG. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med. 1989;86:15–9.CrossRefGoogle Scholar
  32. 32.
    Thabit AK, Nicolau DP. Impact of vancomycin faecal concentrations on clinical and microbiological outcomes in Clostridium difficile infection. Int J Antimicrob Agents. 2015;46:205–8.  https://doi.org/10.1016/j.ijantimicag.2015.03.016.CrossRefPubMedGoogle Scholar
  33. 33.
    Rokas KE, Johnson JW, Beardsley JR, Ohl CA, Luther VP, Williamson JC. The addition of intravenous metronidazole to oral vancomycin is associated with improved mortality in critically ill patients with Clostridium difficile infection. Clin Infect Dis. 2015;61:934–41.  https://doi.org/10.1093/cid/civ409.CrossRefPubMedGoogle Scholar
  34. 34.
    Pettit NN, DePestel DD, Fohl AL, Eyler R, Carver PL. Risk factors for systemic vancomycin exposure following administration of oral vancomycin for the treatment of Clostridium difficile infection. Pharmacotherapy. 2015;35:119–26.  https://doi.org/10.1002/phar.1538.CrossRefPubMedGoogle Scholar
  35. 35.
    McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol. 2002;97:1769–75.  https://doi.org/10.1111/j.1572-0241.2002.05839.x.CrossRefPubMedGoogle Scholar
  36. 36.
    Cornely OA, Miller MA, Louie TJ, Crook DW, Gorbach SL. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis. 2012;55:S154–61.  https://doi.org/10.1093/cid/cis462.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Garey KW, Ghantoji SS, Shah DN, Habib M, Arora V, Jiang ZD, et al. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother. 2011;66:2850–5.  https://doi.org/10.1093/jac/dkr377.CrossRefPubMedGoogle Scholar
  38. 38.
    Thabit AK, Housman ST, Burnham CD, Nicolau DP. Association of healthcare exposure with acquisition of different Clostridium difficile strain types in patients with recurrent infection or colonization after clinical resolution of initial infection. J Hosp Infect. 2016;92:167–72.  https://doi.org/10.1016/j.jhin.2015.11.009.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Pharmacy Practice Department, Faculty of PharmacyKing Abdulaziz UniversityJeddahSaudi Arabia
  2. 2.Jeddah Clinic HospitalJeddahSaudi Arabia

Personalised recommendations